Clinical Success of Gilead’s HCV Drug Continues in Late-Stage Studies

February 5, 2013
Gilead Sciences’ push to develop the first and most effective all-oral hepatitis C drug regimen took a big leap forward on fresh positive results from a pair of Phase III studies of sofosbuvir. The 12-week studies, Fission and Neutrino, evaluated the once-daily drug in combination with ribavirin and together with ribavirin and pegylated interferon, respectively. Both studies, which involved treatment-naïve patients with chronic hepatitis C virus (HCV), met their primary efficacy endpoints and showed sofosbuvir was well tolerated, Gilead said Monday.
Drug Industry Daily